Driven by the need for new therapeutic options for cancer patients, our team is harnessing our deep scientific expertise and drug discovery know-how to create first in class protein-protein interaction stabilizer drugs as novel targeted cancer treatments.
Ambagon’s approach selectively augments the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches. Ambagon’s platform approach will also open opportunities to address other major unmet clinical needs.
Ambagon has sites in San Francisco, CA, USA and Eindhoven, Netherlands